Home › Companies › MEREO BIOPHARMA GROUP PLC › 2024-2025
At MEREO BIOPHARMA GROUP PLC's shareholder meeting held May 13, 2025, in the 2024-2025 proxy season, 61 asset managers reported how they voted in their SEC Form N-PX filings, covering 292 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. MEREO BIOPHARMA GROUP PLC's own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — THAT THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS BE APPROVED, ON AN ADVISORY… — the reporting funds and managers cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and MEREO BIOPHARMA GROUP PLC’s Form 8-K, filed May 14, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 13, 2025: 6 items on MEREO BIOPHARMA GROUP PLC’s Form 8-K, filed May 14, 2025: 1 approved · 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025
Explore MEREO BIOPHARMA GROUP PLC in the interactive database Compare manager voting policies
These tallies are MEREO BIOPHARMA GROUP PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 14, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Resolution 3 That the Company's Audit and Risk Committee be authorized to determine PwC's remuneration. | 529,964,075 | 465,987 | -- | 93,758,600 | -- | 99.9% | Not verified | — |
| Resolution 5 That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis. | 519,808,650 | 10,751,162 | -- | 93,628,850 | -- | 98% | Not verified | — |
| Resolution 6 That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis. | 282,263,090 | -- | -- | 0 | -- | 100% | Not verified | — |
| Resolution 7 That Dr. Deepika Pakianathan be re-appointed as a director of the Company. | 492,594,910 | 36,733,627 | -- | 94,860,125 | -- | 93% | Not verified | — |
| Resolution 8 That Dr. Pierre Jacquet be re-appointed as a director of the Company. | 506,321,440 | 23,094,057 | -- | 94,773,165 | -- | 96% | Not verified | — |
| Resolution 9 That Michael Wyzga be re-appointed as a director of the Company. | 452,185,080 | 77,182,392 | -- | 94,821,190 | -- | 85% | Approved | — |
Source: MEREO BIOPHARMA GROUP PLC, Form 8-K, filed with the SEC on May 14, 2025 — read the filing on EDGAR.
Each item below shows how the 61 asset managers that disclosed a MEREO BIOPHARMA GROUP PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MEREO BIOPHARMA GROUP PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
93% Majority: yes · of votes cast
Description as filed by funds: That Dr. Deepika Pakianathan be re-appointed as a director of the Company.
MEREO BIOPHARMA GROUP PLC’s own tally for this item (“Resolution 7 That Dr. Deepika Pakianathan be re-appointed as a director of the Company.”): 492,594,910 for, 36,733,627 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 925,390 for, 2,759,872 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 2,759,872 | 0 | 0 | Against |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
96% Majority: yes · of votes cast
Description as filed by funds: That Dr. Pierre Jacquet be re-appointed as a director of the Company.
MEREO BIOPHARMA GROUP PLC’s own tally for this item (“Resolution 8 That Dr. Pierre Jacquet be re-appointed as a director of the Company.”): 506,321,440 for, 23,094,057 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 3,685,262 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
85% Approved · of votes cast
Description as filed by funds: That Michael Wyzga be re-appointed as a director of the Company.
MEREO BIOPHARMA GROUP PLC’s own tally for this item (“Resolution 9 That Michael Wyzga be re-appointed as a director of the Company.”): 452,185,080 for, 77,182,392 against — passed, per its Form 8-K filed May 14, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the foregoing votes, the shareholders approved Resolutions 1, 2, 3, 4 and 5 and re-elected each of Dr. Deepika Pakianathan, Dr. Pierre Jacquet and Michael Wyzga.”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 897,521 for, 2,787,741 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 2,759,872 | 0 | 0 | Against |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 27,369 | 0 | 0 | Against |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 500 | 0 | 0 | Against |
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: THAT THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS BE APPROVED, ON AN ADVISORY (NON-BINDING) BASIS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 3,685,262 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 45,478,966 | 0 | 0 | 0 | For |
| Janus Henderson | 22,491,633 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 9,265,664 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6,710,429 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 6,684,247 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 3,902,182 | 0 | 0 | 0 | For |
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,435,398 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 1,100,018 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,073,268 | 0 | 0 | 0 | For |
| UBS | 879,025 | 0 | 0 | 0 | For |
| Renaissance | 877,226 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 689,564 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 686,953 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 435,831 | 0 | 0 | 0 | For |
| Artia Global Partners LP | 421,359 | 0 | 0 | 0 | For |
| Knott David M Jr | 319,337 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 223,452 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 214,905 | 0 | 0 | 0 | For |
| Two Sigma | 146,472 | 0 | 0 | 0 | For |
| Fidelity | 83,478 | 0 | 0 | 0 | For |
| J. Goldman & Co LP | 79,387 | 0 | 0 | 0 | For |
| Graham Capital Management, L.P. | 50,845 | 0 | 0 | 0 | For |
| Citadel | 49,085 | 0 | 0 | 0 | For |
| Clear Harbor Asset Management, LLC | 42,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 55 managers: 106,262,093 for, 6,588 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
100% Majority: yes · of votes cast
Description as filed by funds: THAT THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS BE APPROVED, ON AN ADVISORY (NONBINDING) BASIS.
MEREO BIOPHARMA GROUP PLC’s own tally for this item (“Resolution 6 That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.”): 282,263,090 for, 0 withheld, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 100% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Tema ETF Trust | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| ETFis Series Trust I | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 8 managers: 3,048,600 1 year, 636,662 3 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 31,950,000 | 0 | 0 | 0 | For |
| Janus Henderson | 0 | 0 | 0 | 0 | -- |
| Frazier Life Sciences Management, L.P. | 0 | 0 | 0 | 0 | -- |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| ALKEON CAPITAL MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| GREAT POINT PARTNERS LLC | 0 | 0 | 1,100,018 | 0 | Abstain |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| UBS | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Integral Health Asset Management, LLC | 689,564 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 0 | 0 | 0 | 0 | -- |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 0 | 0 | 0 | -- |
| Artia Global Partners LP | 0 | 0 | 0 | 0 | -- |
| Knott David M Jr | 0 | 0 | 0 | 0 | -- |
| Hudson Bay Capital Management LP | 0 | 0 | 0 | 0 | -- |
| PERCEPTIVE ADVISORS LLC | 214,905 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| J. Goldman & Co LP | 0 | 0 | 0 | 0 | -- |
| Graham Capital Management, L.P. | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Clear Harbor Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 54 managers: 32,861,057 for, 1,850 against, 1,100,018 abstained, 39,273,759 3 year, 33,031,376 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the year ended December 31, 2024, be approved.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 3,685,262 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 13,528,966 | 0 | 0 | 0 | For |
| BlackRock | 34,318 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 1,006 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 13,564,290 for.
100% of fund votes cast · no official result
The 2 asset managers below reported 9,281,685 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MANGROVE PARTNERS IM, LLC | 7,988,129 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,293,556 | 0 | 0 | 0 | For |
100% of fund votes cast · no official result
Description as filed by funds: That PricewaterhouseCoopers LLP ("PwC") be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented.
The 8 asset managers below reported 3,685,262 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
99.9% Majority: yes · of votes cast
Description as filed by funds: That the Audit and Risk Committee be authorized to determine PwC's remuneration.
MEREO BIOPHARMA GROUP PLC’s own tally for this item (“Resolution 3 That the Company's Audit and Risk Committee be authorized to determine PwC's remuneration.”): 529,964,075 for, 465,987 against, per its Form 8-K filed May 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 3,685,262 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
100% of fund votes cast · no official result
Description as filed by funds: That the annual report and accounts for the year ended December 31, 2024, together with the directors' report and independent auditor's report thereon, be received and adopted.
The 8 asset managers below reported 3,685,262 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 2,759,872 | 0 | 0 | 0 | For |
| Tema ETF Trust | 636,662 | 0 | 0 | 0 | For |
| BlackRock | 167,159 | 0 | 0 | 0 | For |
| Fidelity | 90,334 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 27,369 | 0 | 0 | 0 | For |
| State Street | 2,359 | 0 | 0 | 0 | For |
| Northern Trust | 1,007 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 500 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 795,001,444 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Aberdeen | 0.35% |
| 2 | Tema ETF Trust | 0.08% |
| 3 | BlackRock | 0.02% |
| 4 | Fidelity | 0.01% |
| 5 | ETFis Series Trust I | <0.01% |
| 6 | State Street | <0.01% |
| 7 | Northern Trust | <0.01% |
| 8 | Blackstone Alternative Investment Funds | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Rubric Capital Management LP | 5.72% |
| 2 | Janus Henderson | 2.83% |
| 3 | Frazier Life Sciences Management, L.P. | 1.17% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 0.84% |
| 5 | Rock Springs Capital Management LP | 0.84% |
| 6 | ALKEON CAPITAL MANAGEMENT LLC | 0.49% |
| 7 | Aberdeen | 0.35% |
| 8 | Goldman Sachs | 0.18% |
| 9 | GREAT POINT PARTNERS LLC | 0.14% |
| 10 | Woodline Partners LP | 0.14% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Rubric Capital Management LP | 13.65% | DEF14A |
| Entities affiliated with Janus Henderson Investors US LLC | 10.77% | DEF14A |
| EcoR1 Capital, LLC | 8.41% | 13G |
| 683 Capital Management, LLC | 8.19% | 13G |
| Entities affiliated with Rock Springs Capital Management LP | 6.04% | DEF14A |
| Entities affiliated with Adage Capital Management LP | 5.48% | DEF14A |
| Entities affiliated with Mangrove Partners IM, LLC | 5.43% | DEF14A |
| BANK OF AMERICA CORP /DE/ | 5.15% | 13G |
| Entities affiliated with Frazier Life Sciences Management L.P. | 5.08% | DEF14A |
| Mangrove Partners IM, LLC | 4.90% | 13G |
Percentages above are of 795,001,444 shares outstanding, as reported by MEREO BIOPHARMA GROUP PLC on its Form 10-Q dated May 12, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MEREO BIOPHARMA GROUP PLC’s 10-Q dated May 12, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
MEREO BIOPHARMA GROUP PLC proxy season coverage: 2024-2025 (this page).
proxyvotesnow.com, “MEREO BIOPHARMA GROUP (MREO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mereo-biopharma-group-plc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.